Yuhan And ProGen Partner To Accelerate The Future Of Innovative Medicines
Yuhan partners with ProGen to develop innovative drugs using NTIG bispecific antibody technology.
Yuhan Corp. has announced a broad R&D collaboration
agreement with ProGen, a company specializing in next-generation obesity and
diabetes treatments using its bispecific antibody platform, NTIG technology.
This partnership aims to develop innovative new drug candidates. This
collaboration will enhance Yuhan's partnership with ProGen, with both companies
jointly working on developing next-generation biologics. They aim to boost
their global market competitiveness through a new drug development committee
composed of drug development experts from both companies.
ProGen's NTIG technology platform is noted for increasing
protein stability and blood half-life, developing multitarget fusion proteins,
and creating dual-target ADCs, making it highly scalable for various diseases.
As part of the agreement, an immuno-oncology bispecific antibody has been
chosen as the initial joint development project, with discussions ongoing to
identify future joint development projects.
Cho Wook-je, CEO of Yuhan Corp. said, “Through this
comprehensive R&D collaboration agreement, we will continue to exchange
technologies and collaborate with ProGen. We look forward to securing a
pipeline of globally competitive and innovative drugs."
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Más de Pharma News
Todos los artículos →
Ab Science revisa los cronogramas de los ensayos tras tres inspecciones GCP
Novo Nordisk firma un acuerdo de $2.6B con Hengrui por un GLP-1 oral
Discussion